High Levels of B Cell Activating Factor During the Peritransplantation Period Are Associated with a Reduced Incidence of Acute Graft-versus-Host Disease following Myeloablative Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 5, 2010, Pages 629-638

  Cho, Byung Sik ^a   Min, Chang Ki ^a   Kim, Hee Je ^a   Lee, Seok ^a   Kim, Yoo Jin ^a   Lim, Ji Young ^a   Jeong, Dae Chul ^a   Cho, Bin ^a   Kim, Hack Ki ^a   Eom, Ki Seong ^a   Cho, Seok Goo ^a   Kim, Dong Wook ^a   Lee, Jong Wook ^a   Min, Woo Sung ^a   Kim, Chun Choo ^a   Chung, Nak Gyun ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Acute graft versus host disease; Allogeneic stem cell transplantation; B cell activating factor

Indexed keywords

B CELL ACTIVATING FACTOR; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; MALE; MYELOABLATIVE CONDITIONING; PREDICTION; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; WHOLE BODY RADIATION;

ACUTE DISEASE; ADOLESCENT; ADULT; B-CELL ACTIVATING FACTOR; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PREDICTIVE VALUE OF TESTS; PROTECTIVE AGENTS; ROC CURVE; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 77951208346     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.11.023     Document Type: Article

References (47)

1. Beatty P.G., Clift R.A., Mickelson E.M., et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985, 313:765-771.
2. Weisdorf D., Hakke R., Blazar B., et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991, 51:1197-1203.
3. Goulmy E., Schipper R., Pool J., et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996, 334:281-285.
4. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98:2043-2051.
5. Cutler C., Giri S., Jeyapalan S., et al. Acute and chronic graft-versus-host disease after allogeneic peripheral blood stem cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001, 19:3685-3691.
6. Przepiorka D., Smith T.L., Folloder J., et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999, 94:1465-1470.
7. Ball L.M., Egeler R.M. Acute GvHD: pathogenesis and classification. Bone Marrow Transplant 2008, 41:S58-S64.
8. Brink R. Regulation of B cell self-tolerance by BAFF. Semin Immunol 2006, 18:276-283.
9. Tangye S.G., Bryant V.L., Cuss A.K., et al. BAFF, APRIL and human B cell disorders. Semin Immunol 2006, 18:305-317.
10. Schiemann B., Gommerman J.L., Vora K., et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001, 293:2111-2114.
11. Gorelik L., Gilbride K., Dobles M., et al. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 2003, 198:937-945.
12. Zhang J., Roschke V., Baker K.P., et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001, 166:6-10.
13. Groom J., Kalled S.L., Cutler A.H., et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002, 109:59-68.
14. Mariette X., Roux S., Zhang J., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003, 62:168-171.
15. Matsushita T., Hasegawa M., Yanaba K., et al. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006, 54:192-201.
16. Lee S.J., Vogelsang G., Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003, 9:215-233.
17. Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005, 105:2973-2978.
18. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006, 108:756-762.
19. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007, 13:6107-6114.
20. Fujii H., Cuvelier G., She K., et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood 2008, 111:3276-3285.
21. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009, 113:3865-3874.
22. Ratanatharathorn V., Logan B., Wang D., et al. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 2009, 145:816-824.
23. Iori A.P., Torelli G.F., De Propris M.S., et al. B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment related mortality of allogeneic peripheral blood stem cell transplantation. Transplantation 2008, 85:386-390.
24. Ferrara J.L., Levine J.E., Reddy P., et al. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
25. Huard B., Schneider P., Mauri D., et al. T cell costimulation by the TNF ligand BAFF. J Immunol 2001, 167:6225-6231.
26. Ng L.G., Sutherland A.P., Newton R., et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004, 173:807-817.
27. Sutherland A.P., Ng L.G., Fletcher C.A., et al. BAFF augments certain Th1-associated inflammatory responses. J Immunol 2005, 174:5537-5544.
28. + T cells in BAFF-transgenic mice suppress T cell effector responses. J Immunol 2009, 182:793-801.
29. Lee S., Cho B.S., Kim S.Y., et al. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007, 13:1083-1094.
30. Lee S., Kim Y.J., Min C.K., et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005, 105:3449-3457.
31. Min C.K., Kim S.Y., Lee M.J., et al. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. Bone Marrow Transplant 2006, 38:149-156.
32. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96:2062-2068.
33. Kim H.J., Min W.S., Cho B.S., et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2009, 15:704-717.
34. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
35. Yoo J.H., Choi S.M., Lee D.G., et al. Prognostic factors influencing infection-related mortality in patients with acute leukemia in Korea. J Korean Med Sci 2005, 20:31-35.
36. Cho B.S., Min C.K., Eom K.S., et al. Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 41:813-820.
37. Choi S.M., Lee D.G., Lim J., et al. Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients. J Korean Med Sci 2009, 24:571-578.
38. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
39. Ye Q., Wang L., Wells A.D., et al. BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. Eur J Immunol 2004, 34:2750-2759.
40. Mackay F., Leung H. The role of the BAFF/APRIL system on T cell function. Semin Immunol 2006, 18:284-289.
41. Xu L.G., Shu H.B. TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kappa B activation and IL-10 production. J Immunol 2002, 169:6883-6889.
42. Pan L., Delmonte J., Jalonen C.K., et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995, 86:4422-4429.
43. Yang Y.G., Dey B.R., Sergio J.J., et al. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest 1998, 102:2126-2135.
44. Nikolic B., Lee S., Bronson R.T., et al. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest 2000, 105:1289-1298.
45. Moser M., Murphy K.M. Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000, 1:199-205.
46. Schultz K.R., Paquet J., Bader S., et al. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995, 16:289-295.
47. Doreau A., Belot A., Bastid J., et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009, 10:778-785.